ESC Professional Premium Access

When to consider AF ablation: outcome and survival in specific cohorts

Event: ESC Congress 2022
Topic: Treatment
Session type: Symposium
Date: 26 August 2022
Time: 08:30 - 10:00

Congress Session

Become an ESC Professional member to access this resource

Become a member

Already a member? Sign in

5 presentations in this session

Does first line atrial fibrillation ablation improve survival in HFrEF?

Speaker: Associate Professor J. Piccini (Durham, US)
Thumbnail

Does first line atrial fibrillation ablation improve survival in HFpEF?

Speaker: Professor G. Hindricks (Leipzig, DE)
Thumbnail

Does first line AF ablation improve outcome in hypertrophic cardiomyopathy patients?

Speaker: Doctor A. Creta (London, GB)
Thumbnail

Does first line AF ablation improve outcome in asymptomatic patients?

Speaker: Professor K. Chun (Frankfurt am Main, DE)
Thumbnail

When to consider AF ablation: outcome and survival in specific cohorts – discussion.

Thumbnail

4 speakers from this session

Associate Professor Jonathan Piccini

Duke University Medical Center, Durham (United States of America)
4 presentations
0 follower

Professor Gerhard Hindricks

Heart Center of Leipzig, Leipzig (Germany)
58 presentations
16 followers

Doctor Antonio Creta

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)
1 presentation
0 follower

Professor Kyoung-Ryul Julian Chun

CardioVascular Center Bethanien (CCB), Frankfurt am Main (Germany)
15 presentations
0 follower

This platform is supported by

logo Novo Nordisk